Service notifications for recommended Technology Appraisals (TAs)
Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.
| NICE Ref | Title | Date Issued by HSCB | |
| TA234 | Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | 05/01/2012 | |
| TA233 | Golimumab for the treatment of ankylosing spondylitis | 20/02/2012 | |
| TA232 | Retigabine for the adjunctive treatment of partial onset seizures in epilepsy | 05/01/2012 | |
| TA230 | Bivalirudin for the treatment of ST-segment-elevation myocardial infarction | 05/01/2012 | |
| TA229 | Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | 05/01/2012 | |
| TA228 | Bortezomib and thalidomide for the firstline treatment of multiple myeloma | 05/01/2012 | |
| TA227 | Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | 05/01/2012 | |
| TA226 | Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma | 05/01/2012 | |
| TA225 | Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs | 20/02/2012 | |
| TA223 | Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | 05/01/2012 | |
| TA222 | Trabectedin for the treatment of relapsed ovarian cancer | 05/01/2012 | |
| TA221 | Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura | 05/01/2012 | |
| TA220 | Golimumab for the treatment of psoriatic arthritis | 20/02/2012 | |
| TA216 | Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | 05/01/2012 | |
| TA215 | Pazopanib for the first-line treatment of advanced renal cell carcinoma | 05/01/2012 | |
| TA208 | Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | 05/01/2012 | |
| TA203 | Liraglutide for the treatment of type 2 diabetes mellitus | 20/02/2012 | |
| TA200 | Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | 05/01/2012 | |
| TA199 | Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | 20/02/2012 | |
| TA198 | Tocilizumab for the treatment of rheumatoid arthritis | 05/01/2012 | |
| TA197 | Dronedarone for the treatment of non-permanent atrial fibrillation | 20/02/2012 | |
| TA195 | Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | 05/01/2012 | |
| TA193 | Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | 05/01/2012 | |
| TA190 | Pemetrexed for the maintenance treatment of non-small-cell lung cancer | 05/01/2012 | |
| TA188 | Human growth hormone (somatropin) for the treatment of growth failure in children | 05/01/2012 | |
| TA187 | Infliximab (review) and adalimumab for the treatment of Crohn’s disease | 05/01/2012 | |
| TA186 | Certolizumab pegol for the treatment of rheumatoid arthritis | 20/02/2012 | |
| TA169 | Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | 05/01/2012 | |
| TA166 | Cochlear implants for children and adults with severe to profound deafness | 05/01/2012 | |
| TA98 | Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents | 14/09/2016 | |
| TA75 | Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | 05/01/2012 | |
| TA23 | Temozolomide for the treatment of recurrent malignant gliomaC | 02/08/2016 | |
| TA20 | Riluzole for the treatment of Motor Neurone Disease | 01/08/2016 | |